Primary ovarian insufficiency: opportunities and prospects for the realization of reproductive function

Tsygankova O.Yu.; Gramovich G.A.

doi:https://doi.org/10.17116/rosakush20252502142

Recommended articles:

Significance of cell therapy in treatment of patients with thin endometrium and Asherman’s syndrome. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):42-48

Comparative analysis of oocyte quality in patients with tubal-peritoneal genesis of infertility in assisted reproductive technology programs. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):41-49

The experience of using the nasal form of GnRH agonists in in vitro fertilization programs. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):79-84

Local cytokine profile of the endometrium in patients with repeated implantation failures and its pharmacological correction by the secretome of peripheral blood mononuclear cells. Russian Journal of Human Reproduction. 2024;(5):46-54

Clinical and anamnestic features of patients with recurrence of deep infiltrative endometriosis. Russian Journal of Human Reproduction. 2024;(5):89-100

The influence of endometriosis on the quality of life and reproductive function of modern woman. Russian Journal of Human Reproduction. 2024;(5):101-107

Modern view on the experimental creation of endometriosis in animal models (own data). Russian Journal of Human Reproduction. 2024;(6):55-60

Experimental modeling, prevention, and treatment of endometriosis-associated adhesion formation in NIH/3T3 fibroblast cell line using bovhyaluronidase azoximer (in vitro). Russian Journal of Human Reproduction. 2024;(6):61-72

The secretome of peripheral blood mononuclear cells in the therapy of patients with “thin” hypoplastic endometrium and infertility. Russian Journal of Human Reproduction. 2024;(6):81-98

Reproductive aspects in the treatment of colorectal endometriosis. Russian Journal of Human Reproduction. 2024;(6):140-148

Abstract:

Primary ovarian insufficiency is a disease characterized by early dysfunction of the ovaries, which, among other things, is manifested by a decrease in ovarian reserve and reproductive potential. Currently, only one method of implementing reproductive function is available for patients with this pathology — in vitro fertilization using donor genetic material. The main difficulties on the way to pregnancy with gametes of one’s own in this disease are the almost complete absence of ovulation, a decrease in the number of antral follicles, ovarian resistance to the effects of endogenous gonadotropins, as well as to any modern methods of controlled ovulation induction. Moreover, the situation is complicated by the fact that the etiology of primary ovarian insufficiency has not been fully studied, therefore, it is almost impossible to predict the likelihood of this pathology in a particular patient before the onset of the disease, when it is still possible to obtain and cryopreservate their own genetic material. Currently, research is actively underway to develop ways to obtain pregnancies with their own oocytes in patients suffering from this disease. These techniques have demonstrated significant results, but larger clinical trials are required to verify the effectiveness and safety of these techniques.

Keywords:

primary ovarian insufficiency (premature ovarian faillure)

infertility

assisted reproductive technologies

activation of primordial follicles

Authors:

Tsygankova O.Yu.

Omsk State Medical University

ORCID: 0000-0002-3553-055X

Gramovich G.A.

Omsk State Medical University

ORCID: 0009-0009-3521-7318

Received:

07.11.2024

Accepted:

13.11.2024

Close metadata

References:

Torrealday S, Kodaman P, Pal L. Premature ovarian insufficiency — an update on recent advances in understanding and management. F1000Res. 2017;6:2069. https://doi.org/10.12688/f1000research.11948.1
Spiridenko G.Yu. Reproductive potential of women with premature ovarian insufficiency. Mediko-farmatsevticheskii zhurnal «Pul’s». 2021;23:8:41-48. (In Russ.). https://doi.org/10.26787/nydha-2686-6838-2021-23-8-41-48
Vo KCT, Kawamura K. Ovarian fragmentation and AKT-stimulation for expansion of fertile lifespan. Front Reprod Health. 2021;2:3:63-77. https://doi.org/10.3389/frph.2021.636771
Hsueh AJW., Kawamura K. Hippo signaling disruption and ovarian follicle activation in infertile patients. Fertil Steril. 2020;114:3:458-464. https://doi.org/10.1016/j.fertnstert.2020.07.031
Hu L, Tan R, He Y, Wang H, Pu D, Wu J. Stem cell therapy for premature ovarian insufficiency: a systematic review and meta-analysis of animal and clinical studies. Arch Gynecol Obstet. 2024;309:2:457-467. https://doi.org/10.1007/s00404-023-07062-0
Kirshenbaum M, Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. J Assist Reprod Genet. 2019;36:11:2207-2215. https://doi.org/10.1007/s10815-019-01572-0
Andreeva EN, Absatarova YuS, Akhmatova RR, Sheremet’eva EV, Mikheev RK, Grigoryan OR. Premature ovarian insufficiency: from the basics of pathogenesis to prospects in treatment. Voprosy ginekologii, akusherstva i perinatologii. 2021;20:5:100-107. (In Russ.).
Salimova MD. Modern concepts of clinical and diagnostic criteria for premature ovarian insufficiency (literature review). Acta Biomedica Scientifica (East Siberian Biomedical Journal). 2020;5:6:42-50. (In Russ.). https://doi.org/10.29413/ABS.2020-5.6.5
Cai Y, Zhang Q, Yu K, Wang Q. Study of serum anti-mullerian hormone in the diagnosis of ovarian reserve function in patients with premature ovarian insufficiency. Biomed Res Int. 2022;1:2:22. https://doi.org/10.1155/2022/3878359
Shagina VN, Blokhina II, Serov IS. A modern view of the syndrome of premature ovarian insufficiency. Molodoi uchenyi. 2020; 37:327:42-44. (In Russ.).
Tanaka Y, Hsueh AJ, Kawamura K. Surgical approaches of drug-free in vitro activation and laparoscopic ovarian incision to treat patients with ovarian infertility. Fertil Steril. 2020;114:6:1355-1357. https://doi.org/10.1016/j.fertnstert.2020.07.029
Makhmadzhonova MO. Diagnosis of premature ovarian insufficiency in women of late reproductive age (to help a practitioner). Mat’ i ditya. 2023;1:2-38. (In Russ.).
Rebar RW. Premature ovarian failure. Obstet Gynecol. 2009;113: 6:1355-1363. https://https://doi.org/10.1097/AOG.0b013e3181a66843
Dubrovina SO. Premature ovarian insufficiency: an arsenal of approaches. Akusherstvo i ginekologiya. 2022;3:13-20. (In Russ.). https://doi.org/10.18565/aig.2022.3.13-20
Fauser Bart CJM. Overview of ovulation induction. Data of access: September 20 2022. https://www.uptodate.com/contents/overview-of-ovulation-induction?source=bookmarks_widget
Devenutto L, Quintana R, Quintana T. In vitro activation of ovarian cortex and autologous transplantation: A novel approach to primary ovarian insufficiency and diminished ovarian reserve. Hum Reprod Open. 2020;1:4:46. https://doi.org/10.1093/hropen/hoaa046
Fàbregues F, Ferreri J, Méndez M, Calafell JM, Otero J, Farré R. In vitro follicular activation and stem cell therapy as a novel treatment strategies in diminished ovarian reserve and primary ovarian insufficiency. Front Endocrinol (Lausanne). 2021;24:11:617. https://doi.org/10.3389/fendo.2020.617704
Christin-Maitre S, Givony M, Albarel F, Bachelot A, Bidet M, Blanc JV, Bouvattier C, Brac de la Perrière A, Catteau-Jonard S, Chevalier N, Carel JC, Coutant R, Donadille B, Duranteau L, El-Khattabi L, Hugon-Rodin J, Houang M, Grynberg M, Kerlan V, Leger J, Misrahi M, Pienkowski C, Plu-Bureau G, Polak M, Reynaud R, Siffroi JP, Sonigo C, Touraine P, Zenaty D. Position statement on the diagnosis and management of premature/primary ovarian insufficiency (except Turner Syndrome). Ann Endocrinol (Paris). 2021;82:6:555-571. https://doi.org/10.1016/j.ando.2021.09.001
Dolmans MM, Cordier F, Amorim CA, Donnez J, Vander Linden C. In vitro activation prior to transplantation of human ovarian tissue: Is it truly effective? Front Endocrinol (Lausanne). 2019;10:520.
Zhao Y, Zhang Y, Li J, Zheng N, Xu X, Yang J, Xia G, Zhang M. Participates in the activation of primordial follicles through mTORC1-KITL signaling. J Cell Physiol. 2018;233:1:226-237. https://doi.org/10.1002/jcp.25868
Ishizuka B. Current understanding of the etiology, symptomatology, and treatment options in premature ovarian insufficiency (POI). Front Endocrinol (Lausanne). 2021;25:1:62. https://doi.org/10.3389/fendo.2021.626924
Wang Y, Yu A, Yu FX. The Hippo pathway in tissue homeostasis and regeneration. Protein Cell. 2017;8:5:349-359. https://doi.org/10.1007/s13238-017-0371-0
Fraison E, Crawford G, Casper G, Harris V, Ledger W. Pregnancy following diagnosis of premature ovarian insufficiency: a systematic review. Reprod Biomed Online. 2019;39:3:467-476. https://doi.org/10.1016/j.rbmo.2019.04.019
Ma S, Meng Z, Chen R, Guan KL. The Hippo Pathway: Biology and Pathophysiology. Annu Rev Biochem. 2019;20:88:577-604. https://doi.org/10.1146/annurev-biochem-013118-111829
Adamyan LV, Dement’eva VO, Smol’nikova VYu, Asaturova AV. New possibilities of surgery in restoring lost ovarian functions in premature ovarian failure in women of reproductive age. Doctor.Ru. 2019;166:11:44-49. (In Russ.).
Seo J, Kim J. Regulation of Hippo signaling by actin remodeling. BMB Rep. 2018;51:3:151-156. https://doi.org/10.5483/bmbrep.2018.51.3.012
Sreerangaraja Urs DB, Wu WH, Komrskova K, Postlerova P, Lin YF, Tzeng CR, Kao SH. Mitochondrial function in modulating human granulosa cell steroidogenesis and female fertility. Int J Mol Sci. 2020;21:10:3592. https://doi.org/10.3390/ijms21103592
Dubinskaya ED, Gasparov AS, Dmitrieva NV, Krylova NM. Intraovarial autoplasmotherapy in patients with low ovarian reserve. Voprosy ginekologii, akusherstva i perinatologii. 2021;20:6:72-81. (In Russ.). https://doi.org/10.20953/1726-1678-2021-6-72-80
Ahmadian S, Sheshpari S, Pazhang M, Bedate AM, Beheshti R, Abbasi MM, Nouri M, Rahbarghazi R, Mahdipour M. Intra-ovarian injection of platelet-rich plasma into ovarian tissue promoted rejuvenation in the rat model of premature ovarian insufficiency and restored ovulation rate via angiogenesis modulation. Reprod Biol Endocrinol. 2020;18:1:78. https://doi.org/10.1186/s12958-020-00638-4
Adamyan LV, Sibirskaya EV, Shcherina AV. Pathogenetic aspects of premature ovarian failure. Russian Journal of Human Reproduction. 2021;27:1:6-12. (In Russ.). https://doi.org/10.17116/repro2021270116
Huang QY, Chen SR, Chen JM, Shi QY, Lin S. Therapeutic options for premature ovarian insufficiency: an updated review. Reprod Biol Endocrinol. 2022;20:1:28. https://doi.org/10.1186/s12958-022-00892-8
Ai G, Meng M, Guo J, Li C, Zhu J, Liu L, Liu B, Yang W, Shao X, Cheng Z, Wang L. Adipose-derived stem cells promote the repair of chemotherapy-induced premature ovarian failure by inhibiting granulosa cells apoptosis and senescence. Stem Cell Res Ther. 2023;14:1:75. https://doi.org/10.1186/s13287-023-03297-5
Huang Q, Liu B, Jiang R, Liao S, Wei Z, Bi Y, Liu X, Deng R, Jin Y, Tan Y, Yang Y, Qin A. G-CSF-mobilized peripheral blood mononuclear cells combined with platelet-rich plasma accelerate restoration of ovarian function in cyclophosphamide-induced POI rats. Biol Reprod. 2019;101:1:91-101. https://doi.org/10.1093/biolre/ioz077
Sheikhansari G, Aghebati-Maleki L, Nouri M, Jadidi-Niaragh F, Yousefi M. Current approaches for the treatment of premature ovarian failure with stem cell therapy. Biomedicine and Pharmacotherapy. 2018;102:254-262.
Ghahremani-Nasab M, Ghanbari E, Jahanbani Y, Mehdizadeh A, Yousefi M. Premature ovarian failure and tissue engineering. J Cell Physiol. 2020;235:5:4217-4226.
Aflatoonian A, Lotfi M, Saeed L, Tabibnejad N. Effects of intraovarian injection of autologous platelet-rich plasma on ovarian rejuvenation in poor responders and women with primary ovarian insufficiency. Reprod Sci. 2021;28:7:2050-2059. https://doi.org/10.1007/s43032-021-00483-9
Zhang Y, Zhou X, Zhu Y, Wang H, Xu J, Su Y. Current mechanisms of primordial follicle activation and new strategies for fertility preservation. Mol Hum Reprod. 2021;27:2:5. https://doi.org/10.1093/molehr/gaab005
Hu KL, Zhao H, Chang HM, Yu Y, Qiao J. Kisspeptin/Kisspeptin receptor system in the ovary. Front Endocrinol. 2018;8:365. https://doi.org/10.3389/fendo.2017.00365
Zhai J, Ding L, Zhao S, Li W, Sun Y, Su S, Zhang J, Zhao H, Chen ZJ. Kisspeptin: a new marker for human preovulation. Gynecol Endocrinol. 2017;33:560-563. https://doi.org/10.1080/09513590.2017.1296129
Bódis J, Koppán M, Kornya L, Tinneberg HR, Török A. Influence of melatonin on basal and gonadotropin-stimulated progesterone and estradiol secretion of cultured human granulosa cells and in the superfused granulosa cell system. Gynecol Obstet Invest. 2001;52:198-202. https://doi.org/10.1159/000052973
Andreeva EN. Therapeutic possibilities in the correction of vegetative disorders and anovulation in premature ovarian insufficiency. Russian Bulletin of Obstetrician-Gynecologist. 2019;19:5:61-67. (In Russ.). https://doi.org/10.17116/rosakush20191905161
Burova NA. A new therapeutic approach in the treatment of premature ovarian insufficiency in women of reproductive age with pelvic inflammatory diseases. RMZh. Mat’ i ditya. 2019;2:1:10-15. (In Russ.).
Cozzolino M, Marin D, Sisti G. New frontiers in IVF: mtDNA and autologous germline mitochondrial energy transfer. Reprod Biol Endocrinol. 2019;17:1:55. https://doi.org/10.1186/s12958-019-0501-z
Fang L, Li Y, Wang S, Yu Y, Li Y, Guo Y, Yan Y, Sun YP. Melatonin induces progesterone production in human granulosalutein cells through upregulation of StAR expression. Aging (Albany NY). 2019;16;11:20:9013-9024. https://doi.org/10.18632/aging.102367
Petryk N, Petryk M. Ovarian rejuvenation through platelet-rich autologous plasma (PRP)-a chance to have a baby without donor eggs, improving the life quality of women suffering from early menopause without synthetic hormonal treatment. Reprod Sci. 2020;7:11:1975-1982. https://doi.org/10.1007/s43032-020-00266-8